Cerevel Therapeutics and Cyclica Announce Research Collaboration to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience

脑治疗与循环利用人工智能加速神经科学新药的发现

2020-07-27 20:30:18 BioSpace

本文共2709个字,阅读需7分钟

Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines BOSTON & TORONTO--(BUSINESS WIRE)-- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Cyclica, whose AI-augmented, integrated platform enables multi-objective, polypharmacology-informed design of drug molecules, today announced a research collaboration aimed at accelerating the discovery of novel medicines for neuroscience diseases. Through this collaboration, Cerevel will use Cyclica’s Ligand Express and Ligand Design proprietary AI platforms to screen, identify, design and evaluate compounds directed at pre-specified targets for neuroscience diseases. “Cerevel aims to be the premier neuroscience company by applying state-of-the-art technology and a differentiated approach to developing novel medicines,” said John Renger, Ph.D., chief scientific officer at Cerevel Therapeutics. “We are using Cyclica’s world-class AI platform for high throughput screening in compound identification and optimization—which we believe can more efficiently identify new therapeutic molecules with symptomatic or disease-modifying potential. Utilizing cutting-edge tools like Cyclica’s is one of the many ways we are creating a leading neuroscience drug discovery and development platform for the future.” “Leveraging Cyclica’s multi-targeted, proteome-wide approach, combined with Cerevel’s novel and relentless pursuit of advancing neuroscience, has the potential to bring medicines to patients suffering from neurological diseases faster,” said Vern De Biasi, vice president and global head of strategic partnerships at Cyclica. In addition to its pipeline of five clinical assets and seven pre-clinical programs, Cerevel is pursuing undisclosed targets for numerous neurological indications, including those with disease-modifying potential. Cerevel is supporting these efforts through the use of AI, as well as human genetic analyses and DNA-encoded chemical libraries, to better understand the therapeutic potential of numerous chemical lead series. “AI-based in silico drug design has made dramatic progress over the past five years and can significantly enhance our approach to designing potent and selective small molecules based upon predicted three-dimensional structure of protein targets,” said David Stone, head of genetics and biomarkers at Cerevel Therapeutics. “We will use Cyclica’s AI platforms to rapidly generate unique chemical matter for synthesis and testing, with the goal of faster development of new medicines for patients living with neuroscience diseases.” “Cyclica’s drug discovery platform accelerates pre-clinical drug development by considering the polypharmacological profiles and medicinal properties of drug candidates simultaneously during the design process,” said Vijay Shahani, director of applied science at Cyclica. “We are excited by the opportunity to combine our technological approach with Cerevel’s strong expertise in neuroscience to drive the development of meaningful therapeutics.” Terms of the collaboration with Cyclica are not disclosed. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s disease, epilepsy, schizophrenia and substance use disorder. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com. About Cyclica Cyclica is the first company to approach polypharmacology with a structure-based, AI-augmented in silico discovery platform, centered on Ligand Design and Ligand Express. Powered by MatchMaker™, a proprietary deep learning proteome screening technology, and POEM™, an innovative supervised learning technology for predicting molecular properties, Cyclica’s platform is suited uniquely to the design of novel, chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a world-class team that has deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential of artificial intelligence platforms to accelerate the discovery and development of novel medicines for neuroscience diseases. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005180/en/ Cerevel Investor Contact: Matthew Calistri Cerevel Therapeutics matthew.calistri@cerevel.com Cerevel Media Contact: Rachel Eides W2O pure reides@purecommunications.com Cyclica Contact: Jennifer Sacco jennifer.sacco@cyclicarx.com Source: Cerevel Therapeutics and Cyclica View this news release online at: http://www.businesswire.com/news/home/20200727005180/en
Cerevel 将利用 Cyclica 的 Ligand Express ®和 Ligand Design ™平台筛选、识别、评估和优化目标,开发神经科学药物 波士顿和托龙--(商业前景)---- Cerevel Therapeutics ,一家致力于解开大脑治疗神经科学疾病的奥秘的公司,以及 Cyclica ,其人工智能增强的集成平台,能够实现药物分子的多目标、多疾病信息的设计,今天宣布了一项旨在加速发现神经科学疾病新药的研究合作。通过这种合作, Ceresvel 将使用 Cyclica 的 Ligand Express 和 Ligand Design 专有人工智能平台,筛选、识别、设计和评估针对神经科学疾病预定目标的化合物。 Cervel Therapeutics 首席科学官约翰•伦格( John Renger )说:“ Cervel 的目标是通过应用最新技术和差异化方法开发新药,成为一流的神经科学公司。”“我们正在使用 Cyclica 的世界级 AI 平台进行高通量筛选,以进行化合物识别和优化——我们认为,这可以更有效地识别具有症状或疾病改变潜力的新治疗分子。利用像 Cyclica ’ s 这样的尖端工具,是我们为未来创建领先的神经科学药物研发平台的众多方式之一。” Cyclica 副总裁兼全球战略伙伴关系主管 Vern De Biasi 表示:“利用 Cyclica 多目标、全蛋白组学的方法,再加上 Cervel 对推进神经科学的新颖而不懈的追求,有可能更快地为患有神经疾病的患者提供药物。” 除了拥有5个临床资产和7个临床前项目的管道外, Cerevill 正在为众多的神经适应症寻找未披露的目标,包括那些具有疾病改变潜能的适应症。Cerevel 通过人工智能以及人类基因分析和 DNA 编码的化学库来支持这些努力,以更好地了解许多化学先导系列的治疗潜力。 Cerevill Therapeutics 遗传学和生物标记物主管戴维•斯通( David Stone )表示:“过去5年,基于人工智能的硅油药物设计取得了显著进展,能够显著增强我们基于预测的蛋白质目标三维结构设计强分子和选择性小分子的方法。”“我们将利用 Cyclica 的人工智能平台,快速生成用于合成和测试的独特化学物质,目标是为神经科学疾病患者更快地开发新药。” Cyclica 应用科学主管 Vijay Shahani 表示:“ Cyclica 的药物发现平台通过在设计过程中同时考虑药物候选者的多病谱和药物特性,加速临床前药物开发。”“我们很高兴有机会将我们的技术方法与 Cervel 在神经科学方面的强大专业知识结合起来,推动有意义的疗法的发展。” 与 Cyclica 的合作条款未披露。 关于智能治疗 CerevillTherapeutics 致力于揭开大脑治疗神经科学疾病的神秘面纱。公司通过了解神经科学疾病的神经回路及相关症状,寻求释放围绕新治疗机会的科学, Cervel Therapeutics 拥有五个临床阶段研究疗法和几个可能治疗一系列神经科学疾病的临床前化合物组成的多元化管道。包括帕金森病、癫痫、精神分裂症和药物使用障碍。总部位于波士顿的 Cervel Therapeutics 正在推进其目前的研发项目,同时通过内部研究、外部合作或潜在收购探索新模式。有关详细信息,请访问 www.cerevel.com 。 关于 Cyclica Cyclica 是第一家以 Ligand Design 和 Ligand Express 为核心,以基于结构的、人工智能增强的硅胶发现平台为基础,进行多脏病学研究的公司。Cyclica 的平台由 MatchMaker ™(一种专有的深度学习蛋白质组筛选技术)和 POEM ™(一种用于预测分子特性的创新监督学习技术)提供支持,独特地适合于新的设计。化学物质通过同时根据化合物的在靶和非靶向多药结构以及它们的发展特性来排列化合物的优先次序。Cyclica 拥有世界一流的团队,在行业内有着深厚的根基、一流的平台和创新的分散合作模式,正在为未满足的患者需求创造更加精准的药品。 有关前瞻性陈述的特别说明 本新闻稿包含前瞻性声明,这些声明基于管理层的信念和假设以及管理层目前可获得的信息。在某些情况下,您可以通过以下几个词来识别前瞻性陈述:“可能”、“将”、“可能”、“可能”、“将”、“应该”、“预期”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜力”、“继续”、“正在进行”或这些术语或其他类似术语的负值,虽然并非所有前瞻性陈述都包含这些词语。这些声明涉及风险、不确定性和其他可能导致实际结果、活动水平、业绩或成就与这些前瞻性声明所表达或暗示的信息存在重大差异的因素。虽然我们相信,我们对本新闻稿所载的每一项前瞻性声明都有合理的基础,但我们提醒阁下,这些陈述是基于我们目前所知的事实和因素以及我们对未来的预测,我们无法确定。本新闻稿中的前瞻性声明包括但不限于关于人工智能平台加速发现和开发神经科学疾病新药的潜力的声明。我们无法向您保证,本新闻稿中的前瞻性陈述将被证明是准确的。此外,如果前瞻性陈述被证明是不准确的,那么不准确可能是重大的。鉴于该等前瞻性陈述存在重大不确定性,阁下不应将该等陈述视为我们或任何其他人士对我们将于任何指定时间框架内实现目标及计划的陈述或保证,或本新闻稿中的前瞻性陈述代表了我们截至本新闻稿发布之日的观点。我们预期随后的事件和事态发展将使我们的观点发生变化。然而,尽管我们可能选择在未来某个时刻更新这些前瞻性陈述,但我们目前无意这样做,除非适用法律要求。因此,您不应依赖这些前瞻性陈述来代表我们对本新闻稿发布日期之后的任何日期的看法。 查看 businesswire 上的源代码。com : https://www.businesswire.com/news/home/20200727005180/en/ 神奇投资者联系方式: Matthew Calistry 智能治疗学 马修斯。calindi @ cerevel.com 华锐传媒联系人: Rachel Eides W2O 纯 reides @ purecommunications.com 周期性接触: Jennifer Sacco 珍妮弗。sacco @ cyclecarx.com 资料来源:脑部治疗及循环系统 在线查看本新闻稿,网址为: http://www.businesswire.com/news/home/2020072700518/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文